Winrevair access in Pakistan: the DRAP named-patient pathway
How Pakistan patients legally obtain Winrevair (sotatercept-csrk) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Winrevair (sotatercept-csrk) is activin signalling inhibitor (activin receptor type IIA-Fc fusion protein) approved by the US FDA in March 2024 for pulmonary arterial hypertension (PAH; WHO Group 1) in adults to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The drug is manufactured by Merck. Pakistan patients use the Drug Regulatory Authority of Pakistan named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates the US-side sourcing through a DSCSA-compliant specialty channel, builds the documentation packet your physician needs to file, and orchestrates the logistics into Pakistan with a single named coordinator carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Pakistani patients need Winrevair through the named-patient pathway
Pakistan operates a developed pharmaceutical regulatory environment, and Winrevair may be on the local register, may be in commercial review, or may be entirely absent depending on the stage of Merck's regional rollout. Several patterns drive cross-border requests. First, indication lag: newer indications, particularly the March 2024 FDA approval timeline, often reach local registration 12 to 36 months later. Second, biomarker-defined eligibility: no specific companion diagnostic; PAH diagnosis is confirmed by right heart catheterisation can be the diagnostic gate, and where the relevant testing infrastructure is still maturing locally, families coordinate the workup before or in parallel with sourcing. Third, payer coverage: Adamjee Insurance, EFU Health, Jubilee, IGI, State Life, TPL, Salaam Takaful, and the Sehat Sahulat Program for eligible beneficiaries each assess specialty therapies case by case, and step-therapy criteria can fail even where the drug is registered. Fourth, stocking gaps: the local agent may not carry every presentation or dose strength reliably, and named-patient import is the operational mechanism that bridges to the exact label the prescriber has written. In each pattern, the named-patient pathway is the legal mechanism that connects a Pakistani-licensed physician's clinical decision with US-sourced, FDA-labelled product for a specific identified patient.
The DRAP named-patient pathway for Winrevair
The Drug Regulatory Authority of Pakistan (DRAP) administers personal-use imports under the DRAP Act 2012 read with the Drugs Act 1976. The Special Permission or NOC for Personal Use Import is filed via the DRAP OIES portal at dra.gov.pk and routes through the DRAP Division of Pharmacy Services. The framework permits hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and either a clinically equivalent locally registered alternative is not suitable, or the patient's clinical profile does not match the locally approved label.
A complete application for Winrevair typically includes a clinical justification letter from the treating physician documenting the patient's diagnosis (pulmonary arterial hypertension (PAH; WHO Group 1)), severity assessment, prior systemic therapy history, any relevant biomarker results (no specific companion diagnostic; PAH diagnosis is confirmed by right heart catheterisation), and a clinical rationale for selecting Winrevair over locally available alternatives. The Pakistani physician's licensure with the Pakistan Medical Commission (PMC) and the relevant provincial healthcare regulators (Sindh Healthcare Commission, Punjab Healthcare Commission) is verified through the application. The packet also specifies the dispensing facility name and license number, the pharmacy in charge of the facility, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity, intended treatment duration), and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.
For Winrevair specifically, the clinical justification typically frames the case around Winrevair is the first activin-signalling-inhibitor in PAH and was added to triple-therapy backbones in STELLAR; named-patient routing typically reflects PAH centres seeking the latest add-on agent on top of established triple therapy where the local register has not yet caught up. Approval timelines are typically 15 to 30 business days for routine cases; FX timing and bank documentation often govern wire scheduling more than DRAP itself. The DRAP retains discretion on timing, and we do not promise specific durations.
Where Winrevair gets dispensed in Pakistan
A focused group of Pakistan institutions handle named-patient specialty-medicine imports as established workflow, with in-house import pharmacy capabilities and physicians experienced with the application set. For Winrevair specifically, the dispensing facility must accommodate the administration profile: tertiary PAH specialty centre; SC injection administered in clinic during titration, then can transition to home administration after stable dosing is established; regular platelet count, haemoglobin, and right ventricular function surveillance. Tertiary centres that meet this profile include Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in Lahore and Peshawar, Aga Khan University Hospital (AKUH) in Karachi, Liaquat National Hospital in Karachi, Indus Hospital in Karachi, Doctors Hospital Lahore, Hameed Latif Hospital, Shifa International Hospital in Islamabad, and Quaid-e-Azam International Hospital.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a licensed pharmaceutical establishment that holds the import licence and files the DRAP application on the prescribing physician's behalf. The medicine then moves under chain-of-custody documentation into the prescribing hospital's outpatient pharmacy for administration.
Real cost picture for Winrevair in Pakistan
US WAC for Winrevair is approximately USD 14,000 per dose, which translates to an annual WAC in the range of approximately USD 250,000 per year for the standard regimen at the labelled dose. The Pakistani rupee has been volatile against the US dollar; 1 USD is approximately 280 PKR as of May 2026 (flagged as indicative; we quote USD primary, and the State Bank of Pakistan outward remittance allowance for medical purposes is a practical sequencing constraint families plan around). On that basis, the drug cost alone is materially significant before logistics, the DRAP permit fees (which are nominal relative to drug cost), the destination dispensing hospital's administration fees, and Reserve Meds' concierge fee (which is itemised separately on every firm quote).
International cold-chain or ambient logistics into Pakistan typically runs in the low to mid four-figure USD range depending on origin, urgency, and packaging requirements. On the insurance side, Adamjee Insurance, EFU Health, Jubilee, IGI, State Life, TPL, Salaam Takaful, and the Sehat Sahulat Program for eligible beneficiaries each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation with documented step-therapy failure. We do not promise coverage from any payer. US manufacturer patient assistance programmes do not extend internationally; cross-border patients pay cash or rely on local payer coverage where available.
Clinical evidence and where Winrevair sits in the treatment landscape
STELLAR (NCT04576988) phase 3 trial demonstrated significant improvements in 6-minute walk distance, NT-proBNP, WHO functional class, and clinical worsening events versus placebo on background PAH therapy. The drug acts as activin signalling inhibitor (activin receptor type IIA-Fc fusion protein), and the dosing schedule is starting 0.3 mg/kg subcutaneous every 3 weeks for the first dose, then 0.7 mg/kg every 3 weeks.
Within the treatment landscape, Winrevair sits alongside endothelin receptor antagonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), soluble guanylate cyclase stimulator (riociguat), prostacyclin pathway agents (epoprostenol, treprostinil, iloprost, selexipag), and the SOTERIA-LIVE long-term follow-up of sotatercept. The choice between targeted therapies in this space depends on the patient's full clinical profile, prior therapy exposure, biomarker status, comorbidities, and the prescriber's judgment. Reserve Meds coordinates whichever therapy the physician has selected; we do not steer prescribing.
Safety surveillance for Winrevair centres on thrombocytopenia (platelet count monitoring at baseline and before each dose; dose adjustment for grade 2 or higher thrombocytopenia), telangiectasia, increased haemoglobin (haematocrit monitoring), gingival bleeding, dizziness, and rash. The dispensing facility and the prescribing physician retain clinical responsibility for monitoring and adverse-event management; Reserve Meds does not provide medical care.
Typical timeline for Winrevair in Pakistan
DRAP routine processing is typically 15 to 30 business days for routine cases; FX timing and bank documentation often govern wire scheduling more than DRAP itself from a complete filing. End-to-end, most cases complete within 4 to 8 weeks from first complete documentation, with first-of-kind cases and complex biomarker-dependent workups potentially extending further. Where the administration setting is tertiary PAH specialty centre, hospital scheduling and infusion-chair availability are additional sequencing factors that families plan around. We do not promise specific durations; the DRAP retains discretion on timing, and shipping windows depend on lane and packaging.
What your Pakistani physician needs to provide
For a Pakistani-licensed specialist prescribing Winrevair through the DRAP pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis (pulmonary arterial hypertension (PAH; WHO Group 1)), the relevant biomarker work (no specific companion diagnostic; PAH diagnosis is confirmed by right heart catheterisation), prior systemic therapy history, the FDA-approved indication being invoked, and the clinical rationale for Winrevair as the appropriate next step.
The letter also specifies the exact dosing plan per the FDA-approved label: starting 0.3 mg/kg subcutaneous every 3 weeks for the first dose, then 0.7 mg/kg every 3 weeks. The monitoring plan references thrombocytopenia (platelet count monitoring at baseline and before each dose; dose adjustment for grade 2 or higher thrombocytopenia), telangiectasia, increased haemoglobin (haematocrit monitoring), gingival bleeding, dizziness, and rash. The treating physician's licence number with the Pakistan Medical Commission (PMC) and the relevant provincial healthcare regulators (Sindh Healthcare Commission, Punjab Healthcare Commission), the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. Where biomarker testing requires reference-lab coordination, the physician documents the assay used and the report; Reserve Meds can route this through a US-side reference laboratory where the regional pathway is unavailable.
Common questions about Winrevair in Pakistan
Will Adamjee Insurance or other major Pakistani insurers cover Winrevair? Each insurer assesses named-patient imports case by case. Some reimburse fully when Winrevair is on their formulary even if not currently stocked; others assess based on step-therapy criteria and biomarker documentation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you, your physician, or your hospital. We do not promise coverage from any payer.
Is Winrevair registered locally in Pakistan? Local registration status changes as Merck pursues regional rollout; even where the drug is registered, the specific indication, presentation, or dosing strength your prescriber has written may not align with what is currently stocked. The DRAP named-patient pathway exists precisely to bridge these gaps for individually identified patients.
What about competitor therapies? The treatment landscape includes endothelin receptor antagonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), soluble guanylate cyclase stimulator (riociguat), prostacyclin pathway agents (epoprostenol, treprostinil, iloprost, selexipag), and the SOTERIA-LIVE long-term follow-up of sotatercept. The choice depends on the patient's full clinical profile and prescriber judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not steer prescribing decisions and we do not have a financial relationship with any specific manufacturer.
How is the cold chain or storage managed? Winrevair ships in validated packaging with continuous temperature logging through the lane where cold-chain handling applies. The handoff ends at the dispensing pharmacy; home storage instructions, where the patient takes the medicine home for self-administration, are part of the patient onboarding kit.
Do US manufacturer patient assistance programmes (such as Merck co-pay or PAP programmes) extend to Pakistan patients? No. US-resident patient assistance programmes are limited to US-resident patients with US prescription coverage by programme design. Cross-border patients pay cash for the drug and the coordination fee, with local payer reimbursement assessed separately.
Can the case be resupplied year over year if the patient responds? Yes. Reserve Meds maintains the case file and re-files DRAP permits at the relevant intervals (or coordinates with the dispensing hospital's pharmacy if they hold the permit). Patients on long-term therapy typically settle into a quarterly or biannual resupply cadence after the first cycle.
What is the administration setting? Tertiary pah specialty centre; sc injection administered in clinic during titration, then can transition to home administration after stable dosing is established; regular platelet count, haemoglobin, and right ventricular function surveillance.
My physician is at a smaller hospital without an internal import pharmacy. Can the case still proceed? Yes. The common pattern is to route through a Dubai, Riyadh, Mumbai, Cairo, Karachi, or other regional licensed pharmaceutical establishment that holds the import licence and files the DRAP application on the prescribing physician's behalf. The medicine moves into the prescribing hospital's outpatient pharmacy under chain-of-custody documentation.
Where Reserve Meds fits in Winrevair cases
Reserve Meds is a US-based concierge coordinator. We do not replace your Pakistani specialist, we do not replace the DRAP, and we do not replace your dispensing pharmacy. For Winrevair specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate logistics into Pakistan, and assign a single named coordinator through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your Pakistani physician has prescribed Winrevair and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.